

IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A medical kit for qualitative or quantitative determination of a drug in a biological fluid, said medical kit comprising:
 - i) a first part coated with a drug conjugate; and
 - ii) a second part which contains a labeled ~~labelled~~ antidrug antibody being the specific binding partner of the drug conjugate and is adapted for receiving said biological fluid, wherein said labeled ~~labelled~~ anti-drug antibody is labeled ~~labelled~~ with gold material ~~and/or~~ latex particles or both.
2. (Currently Amended) [[A]] The medical kit according to claim 1, wherein said drug conjugate is a conjugate between [[said]] a drug and a protein, peptide, polyamine, ceramide, alkyl chain or carbohydrate.
3. (Currently Amended) [[A]] The medical kit according to claim 2, wherein said protein is selected from rabbit serum albumin, bovine serum albumin, ovalbumin, gamma globulin and thyro globulin.
4. (Currently Amended) [[A]] The medical kit according to ~~any one of claims 1-3~~ claim 1, wherein said latex particles are coloured.
5. (Currently Amended) [[A]] The medical kit according to ~~any one of claims 1-4~~ claim 1, wherein said gold material is colloidal gold.
6. (Currently Amended) [[A]] The medical kit according to ~~any one of claims 1-5~~ claim 2, wherein said drug is selected from antihypertensive, antiviral, antimicrobial, antifungal,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

antiinflammatory, antitumor and psychopharmaceutical agents, including corticosteroids, mono- to oligosaccharides, vitamins, provitamins and hormones.

7. (Currently Amended) [[A]] The medical kit according to ~~any one of claims 1-6~~ claim 6, wherein said drug has a molar weight in the range of from 50 to 6000 g/mol, preferably from 100 to 1000 g/mol.

8. (Currently Amended) [[A]] The medical kit according to claim 7, wherein said drug is selected from lisinopril, amilodipine, captopril, enalapril, enalaprilat, ketotifen, sildenafil and fluoxetine.

9. (Currently Amended) [[A]] The medical kit according to ~~any one of claims 1-8~~ claim 1, wherein said second part is a container which ~~either contains~~ consists of a solution of said labeled ~~labelled~~ anti-drug antibody or has its interior at least partially coated with said labeled anti-drug antibody. therewith.

10. (Currently Amended) [[A]] The medical kit according to ~~any one of claims 1-9~~ claim 1, wherein said first part ~~has the shape of~~ consists of a stick, strip, paddle or plate.

11. (Currently Amended) [[A]] The medical kit, according to claim 10, wherein said first part has the shape of a ~~Nunc-Immuno~~TM ~~Stick~~ NUNC-IMMUNOTM STICK.

12. (Currently Amended) [[A]] The medical kit according to ~~any one of claims 1-11~~ claim 10, wherein said first part has a surface of a material selected from polystyrene, polypropylene, nitrocellulose material ~~chemically treated for maximum binding~~.

13. (Currently Amended) [[A]] The medical kit according to claim 12, wherein said material is that used for the surface of a ~~Nunc-Immuno~~TM ~~Stick~~ NUNC-IMMUNOTM STICK.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

14. (Currently Amended) ~~[[A]]~~ The medical kit according to claim 9, wherein said container is tube-shaped.

15. (Currently Amended) ~~[[A]]~~ The medical kit according to ~~any one of claims 1-14~~ claim 1, wherein said biological fluid is blood, serum or urine.

16. (Currently Amended) ~~A method~~ A method utilizing the medical kit according to claim 1 for the qualitative or quantitative determination of a drug in a biological fluid comprising the steps of:

(i) adding the biological fluid to said second part;

(ii) bringing said first part into contact with the biological fluid in said second part for the qualitative and quantitative determination of the drug in the fluid;

(iii) removing said first part from said second part after a predetermined period of time; and

(iv) determining the color change of said first part indicating the qualitative or quantitative determination of the drug in the biological fluid.

17. (Canceled)

18. (Currently Amended) ~~[[A]]~~ The method according to claim ~~[[17]]~~ 16, wherein said predetermined period of time is in the range of from 5 to 60 minutes.

19. (Currently Amended) ~~[[A]]~~ The method according to ~~any one of claims 16-18~~ claim 16, wherein said first part is subsequently developed in order to bring about a potential colour change indicating the level of said drug in said biological fluid.

20. (Currently Amended) ~~[[A]]~~ The method according to ~~any one of claims 16-19~~ claim 16, wherein the method ~~in its entirety~~ is performed at ambient temperature.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

21. (Currently Amended) [[A]] The method according to ~~any one of claims 16-20~~
claim 16, wherein said biological fluid is blood, serum, urine or saliva.

FINNEGAN
ENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

IN THE ABSTRACT

Please replace the Abstract with the new text as follows:

A novel medical kit that overcomes the problem with non-specific binding and interaction, thus providing a highly reliable method for qualitative or quantitative determination of a drug in a biological fluid. The medical kit of this invention comprises a first part coated with a drug conjugate, and a second part containing labeled anti-drug antibody, where the labeled anti-drug antibody is labeled with gold material or latex particles, which is adapted for receiving biological fluid. This kit and method provides a rapid (under 1 hour), sensitive and simple to use system for drug detection from blood, serum, urine or saliva.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com